Исследование мутагенеза химерного гена Р53, индуцированного канцерогеном аристолохиевой кислотой, в клетках гуманизированных мышей HUPR1
![Диссертация: Исследование мутагенеза химерного гена Р53, индуцированного канцерогеном аристолохиевой кислотой, в клетках гуманизированных мышей HUPR1](https://westud.ru/work/5194753/cover.png)
Диссертация
В ходе выполнения диссертационного исследования впервые были созданы гомозиготная (HupkiPro/Pro) и гетерозиготная (HupkiArg/Pro) линии мышей по аллелям химерного гена р53. Получены первичные культуры фибробластов эмбрионов мышей Hupki и иммортализованные клеточные линии, пригодные для изучения мутагенеза при действии канцерогенов, в частности, аристолохиевой кислоты. В этих экспериментах… Читать ещё >
Содержание
- Глава 1. Обзор литературы
- 1. 1. Ген р53 и его связь с развитием опухолей
- 1. 1. 1. р53: история изучения
- 1. 1. 2. Молекулярная организация гена и белка р
- 1. 1. 3. Мутации гена р53 при канцерогенезе и в опухолях
- 1. 1. 4. Функции белка р53 и последствия их нарушения при канцерогенезе
- 1. 2. Характеристика «гуманизированной» линии генетически модифицированных мышей Hupki, содержащих экзоны (с 4-го по 9-й) гена 53 человека
- 1. 3. Аристолохиевая кислота — генотоксический и канцерогенный эффект
- 1. 1. Ген р53 и его связь с развитием опухолей
Список литературы
- Анисимов В.Н. (2003) «Молекулярные и физиологические механизмы старения» С-Петербург Изд.: Наука-468 с.
- Забежинский М.А., Белицкий Г. А., Ревазова Ю. А. (2004) «Принципы отбора и скрининга работников канцерогеноопасных производств / В кн. „Профилактика профессионального рака“ (Составитель: Смулевич В.Б.)-М: Профиздат с.143−178.
- Копнин Б.П. (2000) Мишени действия онкогенов и опухолевых супрессоров: ключ к пониманию базовых механизмов канцерогенеза // Биохимия. Т.65 с.5- 33.
- Напалков Н.П. (1989) „Общая онколония“. Изд. Медицина. 648 с.
- Патрик Шен. (2005) „Образование рака зависит всего лишь от одной молекулы“, (перевод С. Маркеловой). Научно-практический журнал „Невский целитель“.
- Сейц И.Ф., Князев П. Г. (1986) „Молекулярная онкология. Руководство для врачей“. Изд. Медицина. 352 с.
- Чумаков П.М., Иоцова B.C., Георгиев Г. П. (1982) Выделение ДНК, комплементарной мРНКдля мышиного невирусного Т-антигена. //Докл. Акад. Наук СССР 1982, т.267, с.1272 1275. Докл. Акад. Наук СССР
- Addison С., Jenkins J.R., and Stiirzbecher H.W. The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif// Oncogene 1990 — Vol. 5, № 3 — P.423−426.
- Aguilar F., Hussain S.P., and Cerutti P. Aflatoxin B1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. // Proc. Natl. Acad. Sci. U S A 1993 — Vol. 15, № 90(18) — P. 8586−8590.
- Ashcroft M., and Vousden K.H. Regulation of p53 stability // Oncogene 1999 — Vol. 18, № 53 — P. 7637−7643.
- Avigad S., Barel D., Blau O., Malka A., Zoldan M., Мог С., Fogel M., Cohen I.J., Stark В., Goshen Y., Srein J., and Zaizov R. A novel germ line p53 mutation in intron 6 in diverse childhood malignancies//Oncogene 1997-Vol. 14, № 13-P. 1541−1545.
- Balint E.E., and Vousden K.H. (2001) Activation and activities of the p53 tumour suppressor protein // Br. J. Cancer 2001 — Vol. 85, № 12 — P. 1813−1823.
- Baptiste N., Friedlander P., Chen X., and Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells // Oncogene -2002-Vol. 21, № 1 P. 9−21.
- Bargmann C.I., Hung M.C., and Weinberg R.A. The neu oncogene encodes an epidermal growth factor receptor-related protein // Nature 1986 — Vol. 319, № 6050 — P. 226−230.
- Basu A., and Haldar S. The relationship between Bcl2, Bax and p53: consequences for cell cycle progression and cell death // Mol. Hum. Reprod. 1998 — Vol. 4, № 12 — P. 1099−1109.
- Beckman G., Birganter R., Sjalander A., Saha N., Holmberg P.A., Kivela A. and Beckman
- Is p53 polymorphism maintained by natural selection? // Hum. Hered 1994 — Vol. 44, № 5 -P. 266−270.
- Bellamy W.T. Vascular endothelial growth factor as a target opportunity in hematological malignancies // Curr. Opin. Oncol. 2002 — Vol. 14, № 6 — P. 649−656.
- Bensaad K., and Vousden K.H. p53: new roles in metabolism // Trends Cell Biol. 2007 — Vol. 17 № 6-P. 286−291.
- Biros E., Kalina I., Biros I., Kohut A., Bogyiova E., Salagovic J., and Stubna J.
- Polymorphism of the p53 gene within the codon 72 in lung cancer patients // Neoplasma -2001 Vol. 48, № 5 — P. 407−411.
- Blagosklonny M.V. p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect//FAS E В J.-2000-Vol. 14, № 13-P. 1901−1907.
- Bond G.L., and Levine A.J. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans // Oncogene 2007 — Vol. 26, № 9 — P. 1317−1323.
- Brown L., Boswell S., Raj L., and Lee S.W. Transcriptional targets of p53 that regulate cellular proliferation // Crit. Rev. Eukaryot. Gene Expr. 2007 — Vol. 17, № 1 — P. 73−85.
- Burger C. and Fanning E. Specific DNA binding activity of T antigen subclasses varies among different SV40-transformed cell lines // Virology -1983 Vol. 126, № 1 — P. 19−31.
- Campisi J. Cancer and aging: yin, yang, and p53 // Sci. Aging Knowledge Environ. 2002 -Vol. 9, № 1 — P. 1.
- Campisi J. Cellular senescence and apoptosis: how cellular responses might influence aging phenotypes // Exp. Gerontol. 2003 — Vol. 38, № 1−2 — P. 5−11.
- Canman C.E., Gilmer T.M., Coutts S.B., and Kastan M.B. Growth factor modulation of p53-mediated growth arrest versus apoptosis // Genes Dev. 1995 — Vol. 9, № 5 — P. 600−611.
- Carroll R.B. and Gurney E.G. Time-dependent maturation of the simian virus 40 large T antigen-p53 complex studied by using monoclonal antibodies // J. Virol. 1982 — Vol. 44, № 2 -P. 565−573.
- Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., and Wyllie A.H. Thymocyte apoptosis induced by p53-dependent and independent pathways // Nature -1993 Vol. 362, № 6423 — P. 849−852.
- Clarke A.R., and Hollstein M. Mouse models with modified p53 sequences to study cancer and ageing // Cell Death Differ. 2003 — Vol. 10, № 4 — P. 443−450.
- Clayton C.E., Murphy D., Lovett M. and Rigby P.W. A fragment of the SV40 large T-antigen gene transforms // Nature 1982 — Vol. 299, № 5878 — P. 59−61.
- Cheah P.L., and Looi L.M. p53: an overview of over two decades of study // Malays. J. Pathol. -2001 Vol. 23, № 1 — P. 9−16.
- Chen P.L., Chen Y.M., Bookstein R., and Lee W.H. Genetic mechanisms of tumor suppression by the human p53 gene // Science 1990 — Vol. 250, № 4987 — P. 1576−1580.
- Chin L., Pomerantz J., and DePinho R.A. The INK4a/ARF tumor suppressor: one gene two products — two pathways // Trends Biochem. Sci. — 1998 — Vol. 23, № 8 — P. 291−296.
- Cho Y., Gorina S., Jeffrey P.D. and Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations // Science 1994 — Vol. 265, № 5170- P. 346−355.
- Chumakov P.M. Function of the p53 gene: choice between life and death // Biochemistry (Mosc). 2000 — Vol. 65, № 1 — P. 28−40.
- Cullota E. and Koshland D.E.Jr. p53 sweeps through cancer research // Science 1993 -Vol. 262, № 5142-P. 1958−1961:
- Denissenko M.F., Pao A., Tang M., and Pfeifer G.P. Preferential formation of benzoa. pyrene adducts at lung cancer mutational hotspots in P53. // Science 1996 — Vol. 18, № 274(5286) -P. 430−432.
- Denissenko M.F., Chen J.X., Tang M.S., and Pfeifer G.P. Cytosine methylation determines hot spots of DNA damage in the human P53 gene. // Proc. Natl. Acad. Sci. USA- 1997 Vol. 15, № 94(8) — P.3893−3898.
- De Stanchina E., McCurrach M.E., Zindy F., Shieh S.Y., Ferbeyre G., Samuelson A.V., Prives C., Roussel M.F., Sherr C.J., and Lowe S.W. E1A signaling to p53 involves the p19(ARF) tumor suppressor // Genes. Dev. 1998 — Vol. 12, № 15 — P. 2434−2442.
- Donehower L.A., Harvey M., Stagle B.L., McArthur M.J., Montgomery G.A. Jr., Butel J.S. and Bradley A. Mice deficient for p53 are developmental^ normal but susceptible to spontaneous tumours // Nature 1992 — Vol. 356, № 6366 — P. 215−221.
- Donehower L.A., and Bradley A. The tumor suppressor p53 // Biochim. Biophys. Acta. 1993 — Vol. 1155, № 2 — P. 181−205.
- Dridi W., Krabchi K., Gadji M., Lavoie J., Bronsard M., Fetni R., and Drouin R. Dominant negative activity of mutated p53 proteins // Med. Sci. (Paris) 2006 — Vol. 22, № 3 — P. 301 307.
- Dumaz N., Drougard C., Sarasin A., Daya-Grosjean L. Specific UV-induced mutation spectrum in the p53 gene of skin tumors from DNA-repair-deficient xeroderma pigmentosum patients. // Proc. Natl. Acad. Sci. U S A 1993-Vol. 15, № 90(22) — P. 10 529−10 533.
- Dyson N., and Balmain A. Oncogenes and cell proliferation // Curr. Opin. Genet. Dev. 1999 -Vol. 9, № 1 — P. 11−14.
- El-Deiry W.S., Tokino Т., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression // Cell 1993 — Vol. 75, № 4 — P. 817−825.
- El-Deiry W.S. Regulation of p53 downstream genes // Semin. Cancer Biol. 1998 — Vol. 8, № 5 — P. 345−357.
- Feki A., and Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors // Crit. Rev. Oncol. Hematol. 2004 — Vol. 52, № 2 — P. 103−116.
- Felley-Bosco E., Weston A., Cawley H.M., Bennett W.P. and Harris C.C. Functional studies of a germ-line polymorphism at codon 47 within the p53 gene // Am. J. Hum. Genet. 1993 -Vol. 53, № 3 — P. 752−759.
- Fields S. and Jang S.K. Presence of a potent transcription activating sequence in the p53 protein // Science 1990 — Vol. 249, № 4972 — P. 1046−1049.
- Finlay C.A., Hinds P.W., Tan Т.Н., Eliyahu D., Oren M. and Levine A.J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life // Mol. Cell Biol. 1988 — Vol. 8, № 2 — P. 531−539.
- Finlay C.A., Hinds P.W., and Levine A.J. The p53 proto-oncogene can act as a suppressor of transformation // Cell 1989 — Vol. 57, № 7 — P. 1083−1093.
- Finlay C.A. p53 loss of function: implications for the processes of immortalization and tumorigenesis // Bioessays 1992 — Vol. 14, № 8 — P. 557−560.
- Foster B.A., Coffey H.A., Morin M.J. and Rastinejad F. Pharmacological rescue of mutant p53 conformation and function // Science 1999 — Vol. 286, № 5449 — P. 2507−2510.
- Freedman D.A., Wu L., and Levine A.J. Functions of the MDM2 oncoprotein // Cell Mol. Life Sci. 1999 — Vol. 55, № 1 — P. 96−107.
- Frew I.J., Dickins R.A., Cuddihy A.R., Del Rosario M., Reinhard C., O’Connell M.J., and Bowtell D.D. Normal p53 function in primary cells deficient for Siah genes // Mol. Cell Biol. -2002-Vol. 22, № 23-P. 8155−8164.
- Garkavtsev I., Hull C., and Riabowol K. Molecular aspects of the relationship between cancer and aging: tumor suppressor activity during cellular senescence // Exp. Gerontol. 1998 — Vol. 33, № 1−2-P. 81−94.
- Garner R.C. The role of DNA adducts in chemical carcinogenesis // Mutat. Res. 1998 — Vol. 402, № 1−2-P. 67−75
- Gottlieb E. and Oren M. p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53 // EMBO J. 1998 — Vol. 17, № 13 — P. 3587−3596.
- Graeber T.G., Osmanian C., Jacks Т., Housman D.E., Koch C. J, Lowe S.W. and Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours // Nature 1996 — Vol. 379, № 6560 — P. 88−91.
- Greenblatt M.S., Bennett W.P., Hollstein M., and Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis // Cancer Res. 1994 -Vol. 54, № 18 — P. 4855−4878.
- Guimaraes D.P., and Hainaut P. TP53: a key gene in human cancer // Biochimie 2002 Vol. 84, № 1 — P. 83−93.
- Gupta R.C., Reddy M.V. and Randerath K. 32P-postlabeling analysis of non-radioactive aromatic carcinogen-DNA adducts // Carcinogenesis 1982 — Vol. 3, № 9 — P. 1081−1092.
- Gupta R.C. Enhanced sensitivity of 32P-postlabeling analysis of aromatic carcinogen: DNA adducts // Cancer Res. 1985 — Vol. 45, № 11 Pt. 2 — P. 5656−5662.
- Haber D.A. Splicing into senescence: the curious case of p16 and p19ARF // Cell 1997 — Vol. 91, № 5-P. 555−558.
- Hainaut P., and Hollstein M. p53 and human cancer: the first ten thousand mutations // Adv. Cancer Res. 2000 — Vol. 77-P. 81−137.
- Hainaut P., and Klas W. 25 years of p53 research Springer — 2005.
- Halaban R. Rb/E2 °F: a two-edged sword in the melanocyte system // Cancer Metastasis Rev. -2005 Vol. 24, № 2 — P. 339−356.
- Hammond E.M., and Giaccia A.J. Hypoxia-inducible factor-1 and p53: friends, acquaintances, or strangers? // Clin. Cancer Res. 2006 — Vol. 12, № 17 — P. 5007−5009.
- Harley C.B., Futcher A.B., and Greider C.W. Telomeres shorten during ageing of human fibroblasts // Nature 1990 — Vol. 345, № 6274 — P. 458−460.
- Harris C.C., and Hollstein M. Clinical implications of the p53 tumor-suppressor gene // N. Engl. J. Med.-1993-Vol. 329, № 18-P. 1318−1327.
- Harris C.C. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. // Environ. Health. Perspect. 1996 — Vol. 104, № 3 — P. 435−439.
- Harlow E., Williamson N.M., Ralston R., Helfman D.M. and Adams Т.Е. Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53 // Mol. Cell Biol. -1985-Vol. 5, № 7-P. 1601−1610.
- Haupt Y, Maya R, Kazaz A, and Oren M. Mdm2 promotes the rapid degradation of p53 // Nature 1997 — Vol. 387, № 6630 — P. 296−299.
- Hayflick L. The limited in vitro lifetime of human diploid cell strains // Exp. Cell Res. 1965 -Vol. 37-P. 614−636.
- Hergenhahn M., Luo J.-L., and Hollstein M. p53 designer genes for the modern mouse // Cell Cycle 2004 — Vol. 3, № 6 — P. 738−741.
- Hermeking H., Lengauer C., Polyak К., He T.C., Zhang L., Thiagalingam S., Kinzler K.W., and Vogelstein B. 14−3-3 sigma is a p53-regulated inhibitor of G2/M progression // Mol. Cell -1997-Vol. 1, № 1 P. 3−11.
- Hermiking H., and Benzinger A. 14−3-3 proteins in cell cycle regulation // Semin. Cancer Biol. 2006 — Vol. 16, № 3 — P. 183−192.
- Hernandez-Boussard T.M., and Hainaut P. A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. // Environ Health Perspect 1998 — Vol. 106, № 7 — P. 385−391.
- Horn H.F., and Vousden K.H. Cancer: guarding the guardian? // Nature 2004 — Vol. 427, № 6970-P. 110−111.
- Hollstein M., Sidransky D., Vogelstein В., and Harris C.C. p53 mutations in human cancers // Science-1991 Vol. 253, № 5015-P. 49−53.
- Hollstein M.C., Wild C.P., Bleicher F., Chutimataewin S., Harris C.C., Srivatanakul P., and Montesano R. p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand // Int. J. Cancer 1993 — Vol. 53, № 1 — P. 51−55.
- Houghton P.J. and Ogutveren M. Aristolochic acids and aristolactams from aristolochia auricularil/ Phytochemistry -1991 Vol. 30 — P. 253−254.
- Hupp T. R, Meek D. W, Midgley C. A, and Lane D.P. Regulation of the specific DNA binding function of p53 // Cell -1992 Vol. 71, № 5 — P. 875−886.
- Hussain S.P., and Harris C.C. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes // Cancer Res. 1998 — Vol. 58, № 18 — P. 4023−4037.
- Jacks Т., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., and Weinberg R.A. Tumor spectrum analysis in p53-mutant mice // Curr. Biol. 1994 — Vol. 4, № 1 -P. 1−7.
- Jain N., Singh V., Hedau S., Kumar S., Daga M.K., Dewan R., Murthy N.S., Husain S.A., and Das B.C. Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India // Chest. 2005 — Vol. 128, № 6 — P. 3999−4007.
- Jenkins J.R., Rudge K., Chumakov P., and Currie G.A. (1985) The cellular oncogene p53 can be activated by mutagenesis // Nature 1985 — Vol. 317, № 6040 — P. 816−818.
- Jin S., and Levine A.J. The p53 functional circuit // J. Cell Sci. 2001 — Vol. 114 (Pt 23) — P. 4139−4140.
- Kaeser M.D., and Iggo R.D. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo // Proc. Natl. Acad. Sci. USA -2002 Vol. 99, № 1 — P. 95−100.
- Kastan M.B., Onyekwere О., Sidransky D., Vogelstein В., and Craig R.W. Participation of p53 protein in the cellular response to DNA damage // Cancer Res. 1991 — Vol. 51, № 23 Pt. 1 — P. 6304−6311.
- Kim W.Y., and Sharpless N.E. The regulation of INK4/ARF in cancer and aging // Cell 2006- Vol. 127, № 2 P. 265−275.
- Kleihues P., Aguzzi A., Ohgaki H. Genetic and environmental factors in the etiology of human brain tumors. // Toxicol. Lett. 1995 — Vol. 82−83 — P. 601−605.
- Kleihues P., Schauble В., zur Hausen A., Esteve J., and Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families // Am. J. Pathol. 1997 — Vol. 150, № 1 — P. 1−13.
- Kluthe R., Voht A. and Batsford S. Doppelblindstudie zur Beeinflussung der Phagozytoseaktivitat von Granulocyten durch Aristolochiasaure // Drug Res. 1982 — Vol. 32 -P. 443−445.
- Ко L.J., and Prives C. p53: puzzle and paradigm // Genes. Dev. 1996 — Vol. 10, № 9 — P. 1054−1072.
- Koh J., Enders G.H., Dynlacht B.D., and Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition // Nature 1995 — Vol. 375, № 6531 — P. 506−510.
- Koushik A., Piatt R.W., and Franco E.L. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review // Cancer Epidemiol. Biomarkers Prev. 2004 — Vol. 13, № 1 — P. 11−22. '
- Krumbiegel G., Hallensleben J., Mennicke W.H., Rittmann N., and Roth H.J. Studies on the metabolism of aristolochic acids I and II //Xenobiotica 1987-Vol. 7, № 8 — P. 981−991.
- Kubbutat M.H., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2 // Nature 1997 — Vol. 387, № 6630 — P. 299−303.
- Kuerbitz S.J., Plunkett B.S., Walsh W.V., and Kastan M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. // Proc Natl Acad Sci USA.- 1992 Vol. 15, № 89(16)-P. 7491−7495.
- Kumar S., Walia V., Ray M. f and Elble R.C. p53 in breast cancer: mutation and countermeasures // Front. Biosci. 2007 — Vol. 12 — P. 4168−4178.
- Kussie P. H, Gorina S., Marechal V., Elenbaas В., Moreau J., Levine A.J., and Pavletich
- Malkin D. p53 and the Li-Fraumeni syndrome // Cancer Genet. Cytogenet. 1993 — Vol. 66, № 2 — P. 83−92.
- McDaniel Т., Carbone D., Takahashi Т., Chumakov P., Chang E.N., Pirollo K.F., Yin J., Huang Y. f and Meltzer S.J. The Mspl polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products // Nucleic Acids Res. 1991 — Vol. 19, № 17 — P. 4796.
- Marin M.C., Jost C.A., Brooks L.A., Irwin M.S., O’Nions J., Tidy J.A., James N., McGregor J.M., Harwood C.A., Yulug I.G., Vousden K.H., Allday M.J., Gusterson В., 126. Ikawa S.,
- Hinds P.W., Crook Т., and Kaelin W.G.Jr. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour // Nat. Genet. 2000 — Vol. 25, № 1, P. 47−54.
- Mavridou D., Gornall R., Campbell I.G., and Eccles D.M. TP53 intron 6 polymorphism and the risk of ovarian and breast cancer // Br. J. Cancer 1998 — Vol. 77, № 4 — P. 676−677.
- Mengs UM Lang W. and Poch J.A. The carcinogenetic action of aristolochic acid in rats // Arch. Toxicol. 1982 — Vol. 51 — P. 107−119.
- Mengs U. On the histopathogenesis of rat forestomach carcinoma caused by aristolochia acid // Arch. Toxicol. 1983 — Vol. 52 — P. 209−220.
- Mengs U. Acute toxicity of aristolochic acid in rodents // Arch. Toxicol. 1987 — Vol. 59, № 5 -P. 328−331.
- Mengs U., and Stotzem C.D. Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology // Arch. Toxicol. 1993 — Vol. 67, № 5 — P. 307−311.
- Metcalfe A.M., Dixon R.M., and Radda G.K. Wild-type but not mutant p53 activates the hepatocyte growth factor/scatter factor promoter // Nucleic. Acids Res. 1997 — Vol. 25, № 5 -P. 983−986.
- Milner J, and Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation // Cell 1991 — Vol. 31, № 65(5) — P.765−774.
- Miyashita Т., and Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene // Cell 1995 — Vol. 80, № 2 — P. 293−299.
- Momand J., Zambetti G.P., Olson D.C., George D., and Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation // Cell -1992 Vol. 69, № 7 — P. 1237−1245.
- Molinari A., and Milner J. p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6 // Oncogene 1995 — Vol. 4, № 10(9) — P. 1849−1854.
- Moll U.M., Ostermeyer A.G., Haladay R., Winkfield В., Frazier M., and Zambetti G.
- Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. // Mol Cell Biol. 1996 — Vol. 16, № 3 — P. 1126−1137.
- Momand J., and Zambetti G.P. Mdm-2: „big brother“ of p53 // J. Cell Biochem. 1997 — Vol. 64, № 3 — P. 343−352.
- Montesano R., Hainaut P., and Hall J. Chemical-induced genetic alterations in human cancers: relevance to aetiology and pathogenesis. // Eur. J. Cancer Prev. -1996 Vol. 5, № 5 -P. 392−393.
- Montesano R., Hainaut P., and Wild C.P. Hepatocellular carcinoma: from gene to public health // J. Natl. Cancer Inst. 1997 — Vol. 89, № 24 — P. 1844−1851.
- Mose D.L. Weitere Untersuchungen uber die Wirkung der Aristolochiasaure // Drug Res. -1966-Vol. 16-P. 118−122.
- Mose D.L. and Porte J. Weitere Studien iiber Aristolochiasaure // Drug Res. 1974 — Vol. 24 -P. 151−153.
- Morgan S.E. and Kastan M.B. p53 and ATM: cell cycle, cell death, and cancer // Adv. Cancer Res. 1997-Vol. 71-P. 1−25.
- Murphy M.E. Polymorphic variants in the p53 pathway // Cell Death Differ. 2006 — Vol. 13, № 6-P. 916−920.
- Nam D.H., Park K., Suh Y.L., and Kim J.H. Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance // Oncol. Rep. 2004 — Vol. 11, № 4 — P. 863−869.
- Nelson W.G., and Kastan M.B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways // Mol. Cell Biol. 1994 — Vol. 14, № 3 — P. 1815−1823.
- Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., and Devilee P. Mutations in the p53 gene occur in diverse human tumour types. // Nature. 1989 — Vol. 7, № 342(6250) — P. 705−708.
- Nortier J.L., Martinez M.C., Schmeiser H.H. and Arlt V.M. Urotelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi) II New Engl. J. Med. 2000 — Vol. 343 — P. 1686−1692.
- Okamura S., Arakawa H., Tanaka Т., Nakanishi H., Ng C.C., Taya Y., Monden M., Nakamura Y. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis // Mol. Cell 2001 — Vol. 8, № 1 — P. 85−94.
- Oliner J.D., Kinzler K.W., Meltzer P. S., George D.L., and Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. // Nature 1992 — Vol. 2, № 358(6381) — P. 80−83.
- Oren M. and Levine A.J. Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen // Proc. Natl. Acad. Sci. U S A. 1983 — Vol. 80, № 1 — P. 56−59.
- Oren M., Beinz.B., Givol D., Rechavi G. and Zakut R. Analysis of recombinant DNA clones specific for the murine p53 cellular tumor antigen // EMBO J. 1983- Vol. 2, № 10 — P. 16 331 639.
- Oren M. p53: the ultimate tumor suppressor gene? // FASEB J. 1992 — Vol. 6, № 13 — P. 3169−3176.
- Oren M. Decision making by p53: life, death and cancer // Cell Death Differ. 2003 — Vol. 10, № 4-P. 431−442.
- O’Reilly D.R. p53 and transformation by SV40 // Biol. Cell 1986 — Vol. 57, № 3 — P. 187−196.
- O’Rourke R.W., Miller C.W., Kato G.J., Simon K.J., Chen D.L., Dang C.V. and Koefflen H.P.
- A potential transcriptional activation element in the p53 protein // Oncogene 1990 — Vol. 5, № 12-P. 1829−1832.
- Pailer M.L., Belohlav L. and Simonitsch E. Zur Konstitution der Aristolochiasauren // Monatsh.Chem. 1955 — Vol. 86 — P. 676−680.
- Palmero I., Pantoja C., and Serrano M. p19ARF links the tumour suppressor p53 to Ras // Nature 1998 — Vol. 395, № 6698 — P. 125−126.
- Peller S., Kopilova Y., Slutzki S., Halevy A., Kvitko K., and Rotter V. A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility // DNA Cell Biol. 1995 — Vol. 14, № 12 — P. 983−990.
- Pennica D., Goeddel D.V., Hayflick J.S., Reich N.C., Anderson C.W. and Levine A.J. Theamino acid sequence of murine p53 determined from a c-DNA clone // Virology 1984 — Vol. 134, № 2-P. 477−482.
- Pfau W., Schmeiser H.H., and Wiesller M. Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA // Carcinogenesis 1990 — Vol. 11, № 2 — P. 313 319.
- Pfau W., Schmeiser H.H., and Wiesller M. 32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II // Carcinogenesis 1990 — Vol. 11, № 9 — P. 1627−1633.
- Phillips D.H., and Arlt V.M. The 32P-postlabeling assay for DNA adducts. II Nat. Protoc. -2007 Vol. 2, № 11 — P. 2772−2781.
- Piette J., Neel H. and Marechal V. Mdm2: keeping p53 under control // Oncogene 1997 -Vol. 15, № 9-P. 1001−1010.
- Pietsch E. C, Humbey O., and Murphy M.E. Polymorphisms in the p53 pathway // Oncogene -2006-Vol. 25, № 11 P. 1602−1611.
- Pirn D., and Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression // Int. J. Cancer 2004-Vol. 108, № 2 — P. 196−199.
- Poirier M.C., and Weston A. Human DNA adduct measurements: state of the art // Environ. Health Perspect.- 1996 Vol. 5 — P. 883−893.
- Preisler H.D. Resistance to cytotoxic therapy: a speculative overview // Ann. Oncol. 1995 -Vol. 6, № 7 — P. 651−657.
- Priestap H.A. Minor Aristolochia acid from Aristolochia argentine and mass spectral analysis of aristolochic acid // Phytochemistry 1998 — Vol. 26 — P. 519−529.
- Prives C., and Hall P.A. The p53 pathway // J. Pathol. 1999 — Vol. 187, № 1 — P. 112−126.
- Quelle D.E., Zindy F., Ashmun R.A., and Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest // Cell 1995 — Vol. 83, № 6 — P. 993−1000.
- Randerath К. Reddy M.V., and Gupta R.C. 32P-Iabeling test for DNA damage // Proc. Natl. Acad. Sci. U S A. 1981 — Vol. 78, № 10 — P. 6126−6129.
- Raycroft L., Wu H.Y. and Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene // Science 1990 — Vol. 249, № 4972 — P. 1049−1051.
- Rayter S.I., Iwata K.K., Michitsch R.W., Sorvillo J.M., Valenzuela D.M., and Foulkes J.G.
- Biochemical functions of oncogenes In: Oncogenes — 1989 — (Ed. by Glover D.M., Hames B.D.), Oxford — University Press, New York. P. 23−66.
- Reddy M.V., Gupta R.C., and Randerath K. 32P-base analysis of DNA // Anal. Biochem. -1981 Vol. 117, № 2-P. 271−279.
- Reddy M.V., and Randerath K. Nuclease P1-mediated enhancement of sensitivity of 32P-postlabeling test for structurally diverse DNA adducts // Carcinogenesis 1986 — Vol. 7, № 9 -P. 1543−1551.
- Reich N.C. and Levine A.J. Specific interaction of the SV40 T antigen-cellular p53 protein complex with SV40 DNA // Virology 1982 — Vol. 117, № 1 — P. 286−290.
- Reinbold M., Luo J.L., Nedelko Т., Jerchow В., Murphy M.E., Whibley C., Wei Q., and Hollstein M. Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72 // Oncogene 2008 — Vol. 27, № 19 — P. 2788−2794.
- Reisman D., and Rotter V. Two promoters that map to 5'-sequences of the human p53 gene are differentially regulated during terminal differentiation of human myeloid leukemic cells // Oncogene 1989 — Vol. 4, № 8 — P. 945−953.
- Ren В., Yee K.O., Lawler J., and Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1 // Biochim. Biophys. Acta. 2005 — Vol. 1765, № 2 — P. 178−188.
- Rosenmund H. and Reichstein T. Zur Kenntnis der Aristolochiasaure // Pharm. Acta Helv. -1943-Vol. 18-P. 243−261.
- Romer L., Klein C., Dehner A., Kessler H., and Buchner J. p53—a natural cancer killer: structural insights and therapeutic concepts // Angew. Chem. Int. Ed. Engl. 2006 — Vol. 45, № 39 — P. 6440−6460.
- Royds J.A., and lacopetta B. p53 and disease: when the guardian angel fails // Cell Death Differ. 2006 — Vol. 13, № 6 — P. 1017−1026.
- Rubin H. Cell aging in vivo and in vitro. // Mech. Ageing Dev. 1997 — Vol. 98, № 1 — P. 1−35.
- Rucker G. and Chung B.S. Aristolochic acids from Aristolochia manshuriensis. II Planta Med. -1975-Vol. 27-P. 68−71.
- Russo A.A., Tong L., Lee J.O., Jeffrey P.D., and Pavletich N.P. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a // Nature 1998 -Vol. 395, № 6699 — P. 237−243.
- Sakamuro D., Sabbatini P., White E., and Prendergast G.C. The polyproline region of p53 is required to activate apoptosis but not growth arrest // Oncogene 1997 — Vol. 15, № 8 — P. 887 898.
- Saporita A.J., Maggi L.B. Jr., Apicelli A.J., and Weber J.D. Therapeutic targets in the ARFtumor suppressor pathway // Curr. Med. Chem. 2007 — Vol. 14, № 17 — P. 1815−1827.
- Scata K.A., and El-Deiry W.S. p53, BRCA1 and breast Cancer chemoresistance // Adv. Exp. Med. Biol. 2007 — Vol. 608 — P. 70−86.
- Schmeiser H.H., Schoepe K.-B. and Wissler M. DNA adduct formation of aristolochia acid I and II in vitro and in vivo // Carcinogenesis 1988 — Vol. 9 — P. 297−303.
- Schmeiser H.H., Bieler C.A., Wiesler M., van Ypersele de Strihou C., and Cosyns J.-P.
- Detection of DNA adducts formed by aristolochia acid in renal tissue from patients with Chinese herbal nephropathy // Cancer Res. 1996 — Vol. 56 — P. 2025−2028.
- Schuler M., and Green D.R. Mechanisms of p53-dependent apoptosis // Biochem. Soc. Trans. 2001 — Vol. 29, (Pt 6) — P. 684−688.
- Schuler M., and Green D.R. Transcription, apoptosis and p53: catch-22 // Trends Genet. -2005 Vol. 21, № 3 — P. 182−187.
- Schwetz B.A. From the food and Drug Administration // J. Am. Med. Assoc. 2001 — Vol. 285 -P. 2705.
- Serrano M., Lee H., Chin L., Cordon-Cardo C., Beach D., and DePinho R.A. Role of the INK4a locus in tumor suppression and cell mortality // Cell 1996 — Vol. 85, № 1 — P. 27−37.
- Serrano M., Lin A.W., McCurrach M.E., Beach D., and Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a // Cell 1997 -Vol. 88, № 5 — P. 593−602.
- Sharpless E., and Chin L. The INK4a/ARF locus and melanoma // Oncogene 2003 — Vol. 22, № 20 — P. 3092−3098.
- Sharpless N.E. Ink4a/Arf links senescence and aging // Exp. Gerontol. 2004 — Vol. 39, № 11−12-P. 1751−1759.
- Sharpless N.E. INK4a/ARF: a multifunctional tumor suppressor locus // Mutat. Res. 2005 -Vol. 25, № 576(1−2) — P. 22−38.
- Sharpless N.E., and DePinho R.A. p53: good cop/bad cop // Cell 2002 — Vol. 12, № 110(1)-P. 9−12.
- Sharpless N.E., and DePinho R.A. Cancer: crime and punishment // Nature 2005 — Vol. 436, № 7051 — P. 636−637.
- Shaulsky G., Ben-Ze'ev A., and Rotter V. Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells // Oncogene 1990 — Vol. 5, № 11 — P. 1707−1711.
- Shay J.W. Molecular pathogenesis of aging and cancer: are telomeres and telomerase the connection? // J. Clin. Pathol. 1997 — Vol. 50, № 10, P. 799−800.
- Sheikh M.S., Hollander M.C., and Fornance A. J .Jr. Role of Gadd45 in apoptosis // Biochem. Pharmacol. 2000 — Vol. 59, № 1 — P. 43−45.
- Sjalander A., Birganter R., Kivela A., and Beckman G. p53 polymorphisms and haplotypes in different ethnic groups // Hum. Hered. 1995 — Vol. 45, № 3, — P. 144−149.
- Sjalander A., Birgander R., Hallmans G., Cajander S., Lenner P., Athlin L., Beckman G., and Beckman L. p53 polymorphisms and haplotypes in breast cancer // Carcinogenesis -1996 -Vol. 17, № 6-P. 1313−1316.
- Slee E.A., and Lu X. The ASPP family: deciding between life and death after DNA damage // Toxicol. Lett. 2003 — Vol. 139, № 2−3 — P. 81−87.
- Song H., Hollstein M. and Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM // Nat. Cell Biol. 2007 — Vol. 9, № 5 — P. 573−580.
- Song H., and Xu Y. Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways // Cell Cycle 2007 — Vol. 6, № 13, — P. 1570−1573.
- Soussi T. p53 alterations in human cancer: more questions than answers // Oncogene 2007 -Vol. 26, № 15, — P. 2145−2156.
- Stein G.H., and Dulic V. Origins of G1 arrest in senescent human fibroblasts // Bioessays -1995 Vol. 17, № 6 — P. 537−543.
- Strano S., Dell’orso S., Mongiovi A.M., Monti O., Lapi E., Agostino S.D., Fontemoggi G., and Blandino G. Mutant p53 proteins: Between loss and gain of function // Head Neck 2007 — Vol. 29, № 5 — P. 488−496.
- Strano S., Dell’Orso S., Di Agostino S., Fontemaggi G., Sacchi A., and Blandino G. Mutant p53: an oncogenic transcription factor//Oncogene-2007-Vol. 26, № 15-P. 2212−2219.
- Stiborova M., Fernando R.C., Schmeiser H.H., Frei E., Pfau W., and Wiessler M.
- Characterization of DNA adducts formed by aristolochic acids in the target organ (forestomach) of rats by 32P-postlabelling analysis using different chromatographic procedures // Carcinogenesis 1994 — Vol. 15, № 6 — P. 1187−1192.
- Sturzbecher H. W, Brain R., Addison C., Rudge K., Remm M., Grimaldi M., Keenan E., and Jenkins J.R. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization // Oncogene 1992 — Vol. 7, № 8 — P. 1513−1523.
- Sullivan A., and Lu X. ASPP: a new family of oncogenes and tumour suppressor genes // Br. J. Cancer 2007 — Vol. 96, № 2 — P. 196−200.
- Talis A.L., Huibregtse J.M., and Howley P.M. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. // J Biol Chem. -1998 Vol. 13, № 273(11) — P. 6439−6445.
- Taylor W.R., and Stark G.R. (2001) Regulation of the G2/M transition by p53 // Oncogene -2001 Vol. 20, № 15-P. 1803−1815.
- Tamir Y., and Bengal E. p53 protein is activated during muscle differentiation and participates with MyoD in the transcription of muscle creatine kinase gene // Oncogene 1998 — Vol. 17, № 3-P. 347−356.
- Tarunina M., and Jenkins J.R. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity // Oncogene 1993 Vol. 8, № 11 — P. 3165−3173.
- Tao W., and Levine A.J. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2 // Proc. Natl. Acad. Sci U S A. 1999 — Vol. 96, № 12 — P. 6937−6941.
- Tobiume K. Involvement of Bcl-2 family proteins in p53-induced apoptosis // J. Nippon. Med. Sch. 2005 — Vol. 72, № 4 — P. 192−193.
- Tornaletti S., and Pfeifer G.P. Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer.//Science. 1994-Vol. 11, № 263(5152)-P. 1436−1438.
- Ueda H., Ullrich S.J., Gangemi J.D., Kappel C.A., Ngo L., Feitelson M.A., and Jay G.
- Vanhaelen M., Vanhaelen-Fastre R., But, P., Vanherweghem J-L. Identification of aristolochic acid in Chinese herbs // Lancet 1994 — Vol. 343 — P. 174.
- Vanherweghem J.-L., Depierreux M., and Tielemans C. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs // Lancet 1993 — Vol. 341 — P. 387−391.
- Varley J.M., McGown G., Thorncroft M., Kelsey A.M., and Birch J.M. Significance of intron 6 sequence variations in the TP53 gene in Li-Fraumeni syndrome // Cancer Genet. Cytogenet. -2001 Vol. 129, № 1 — P. 85−87.
- Venot C., Maratrat M., Sierra V., Conseiller E., and Debussche L. Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains//Oncogene 1999-Vol. 18, № 14-P. 2405−2410.
- Viktorsson K., De Petris L., and Lewensohn R. The role of p53 in treatment responses of lung cancer // Biochem. Biophys. Res.Commun. 2005 — Vol. 331, № 3 — P. 868−880.
- Vishwanath B.S., and Gowda T.V. Interaction of aristolochic acid with Vipera russelli phospholipase A2: its effect on enzymatic and pathological activities // Toxicon. 1997 — Vol. 25, № 9 — P. 929−937.
- Vogelstein В., and Kinzler K.W. p53 function and dysfunction // Cell 1992 — Vol. 70, № 4 -P. 523−526.
- Vousden K.H., and Lane D.P. p53 in health and disease // Nat. Rev. Mol. Cell Biol. 2007 -Vol. 8, № 4-P. 275−283.
- Walker K.K., and Levine A.J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression // Proc. Natl. Acad. Sci. USA.- 1996 Vol. 93, № 26 — P. 15 335−15 340.
- Woo R.A., McLure K.G., Lees-Miller S.P., Rancourt D.E., and Lee P.W. DNA-dependent protein kinase acts upstream of p53 in response to DNA damage // Nature 1998 — Vol. 394, № 6694 — P. 700−704.
- Woods D.B., and Vousden K.H. Regulation of p53 function // Exp. Cell Res. 2001 — Vol. 264, № 1 — P. 56−66.
- Wu W.J., Kakehi Y., Habuchi Т., Kinoshita H., Ogawa O., Terachi Т., Huang C.H., Chiang C.P., and Yoshida O. Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers // Jpn. J. Cancer Res. 1995 — Vol. 86, № 8 — P. 730−736.
- Wu X., Bayle J.H., Olson D., and Levine A.J. The p53-mdm-2 autoregulatory feedback loop // Genes. Dev. 1993 — Vol. 7, № 7A-P. 1126−3112.
- Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 // Nature 1991 -Vol. 352, № 6333 — P. 345−347.
- Yu H., Chen J.K., Feng S., Dalgarno D.C., Brauer A.W., and Schreiber S.L. Structural basis for the binding of proline-rich peptides to SH3 domains // Cell 1994 — Vol. 76, № 5 — P. 933 945.
- Xie X.Y., Tan Y.J., and Zhu Y.L. Relation between mutant p53 and multidrug resistance in gastric cancer. // Zhejiang Da Xue Xue Bao Yi Xue Ban. 2006 — Vol. 35, 1 — P. 91−98.
- Zakut-Houri R., Bienz-Tadmor В., Givol D. and Oren M. Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells // EMBO J. 1985 — Vol. 4, № 5 — P. 1251−1255.
- Zielinski В., Liu Z., Hollstein M., Hergenhahn M., and Luo J.-L. Mouse models for generating P53 gene mutation spectra // Toxicol Lett. 2002 — Vol. 134, № 1−3 — P. 31−37.
- Zindy F., Eischen C.M., Randle D.H., Kamijo Т., Cleveland J.L., Sherr C.J., and Roussel M.F. Мус signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization // Genes. Dev. 1998 — Vol. 12, № 15 — P. 2424−2433.
- Zhou Y., Li N. Zhuang W., Liu G.J., Wu T.X., Yao X., Du L» Wei M.L., and Wu X.T. P53codon 72 polymorphism and gastric cancer a meta-analysis of the literature // Int. J. Cancer -2007-Vol. 121, № 7-P. 1481−1486.